摘要
目的:评价苦参素联合核苷类似物治疗慢性乙型肝炎(CHB)的安全性和有效性。方法:计算机检索PubMed、中国生物医学文献数据库(1978-2009)、中文科技期刊全文数据库(1989-2009年)纳入苦参素联合核苷类似物治疗CHB的随机对照试验(RCT)文献,手工检索其他的相关文献,对纳入研究进行方法学质量评价,并采用Rev Man5.0.0软件对其进行Meta分析。结果:共纳入11个RCT,苦参素联合拉米夫定治疗CHB的HBeAg/抗HBe血清转换率,联合组优于单用组[RR2.16,95%CI(1.30,3.59)]。苦参素联合阿德福韦治疗CHB的血清ALT复常率;血清HBV-DNA转阴率;血清HBeAg转阴率;HBeAg/抗HBe血清转换率,联合组均优于单用组,且差异有统计学意义,其RR和95%CI分别为:[RR1.28,95%CI(1.17,1.40)]、[RR1.27,95%CI(1.13,1.42)]、[RR1.80,95%CI(1.32,2.44)]、[RR2.06,95%CI(1.43,2.95)]。苦参素联合恩替卡韦治疗CHB血清ALT复常率和HBeAg/抗HBe血清转换率联合组均显著优于单用组。结论:苦参素联合核苷类似物治疗CHB,能明显提高乙肝患者的HBsAg/抗HBs血清转换率,而达到较好的治疗效果。
OBJECTIVE Review the effect and safety of Kushenin combined with nueleoside analogues for the treatment of chronic hepatitis B （CHB）. METHODS Randomized controlled trails of Kushenin combined with nucleoside analogues for CHB were gathered from PubMed, CBMdisc （1978- 2009）, CNKI （1979- 2009）, while other relative researches were handsearched; every research was evaluated, then analyzed by software of RevMan 5.0. 0. RESULTS Eleven randomized controlled trials were included. The therapeutic effect of kushenin combined with lamivudine was better than that of lamivudine alone, [RR 2. 16, 95GCI （1.30, 3. 59）2 ; Kushenin combined with adefovir dipivoxil improved the effective ratio of the negative rate of serum ALT , the negative rate of serum HCV-DNA, the negative rate of serum HBeAg, the HBeAg and anti-HBe transformation, the RR and 95 % CI of the results were [RR 1.28,95 %CI（ 1.17, 1.40） ], [RR 1.27,95 %CI（ 1.13, 1.42） ], [RR 1.80,95 %4CI（ 1.32, 2. 44）], [RR 2. 06,95%CI（1. 43, 2. 95）]. Kushenin combined with entecavir improved the effective ratio of the negalive rate of serum ALT , the HBeAg and anti HBe transformation. CONCLUSION Kushenin combined with nucle- oside analogues for CHB can improve the effective ratio of the HBeAg and anti-HBe transformation and achieve the better ther apeutic effect.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2011年第1期53-57,共5页
Chinese Journal of Hospital Pharmacy
关键词
苦参素
慢性乙型肝炎
系统评价
Kushenin
chronic hepatitis B
systematic review
